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MicroRNA-497 increases apoptosis in MYCN
amplified neuroblastoma cells by targeting the
key cell cycle regulator WEE1
Laura Creevey1,2, Jacqueline Ryan1,2, Harry Harvey1,2, Isabella M Bray1,2, Maria Meehan1,2, Adnan R Khan3 and
Raymond L Stallings1,2*
Abstract
Background: Neuroblastoma is responsible for 15% of all childhood cancer deaths. Despite advances in treatment
and disease management, the overall 5-year survival rates remain poor in high-risk disease (25-40%). MiR-497 was
previously identified by our laboratory as a member of a miRNA expression signature, predictive of neuroblastoma
patient survival and has been reported as a tumor suppressor in a variety of other cancers. WEE1, a tyrosine kinase
regulator of the cell cycle and predicted target of miR-497, has emerged as an oncogene in several cancer types
and therefore represents an attractive potential target for novel therapy approaches in high-risk neuroblastoma. Our
aim was to investigate the potential tumor suppressive role of miR-497 in high-risk neuroblastoma.
Methods: Expression levels of miR-497 and WEE1 in tissues and cells were determined using RT-PCR. The effect of
miR-497 and siWEE1 on cell viability was evaluated using MTS assays, apoptosis levels were determined using FACS
analysis of Annexin V/PI stained cells, and target protein expression was determined using western blot. Luciferase
reporter plasmids were constructed to confirm direct targeting. Results were reported as mean±S.E.M and
differences were tested for significance using 2-tailed Students t-test.
Results: We determined that miR-497 expression was significantly lower in high-risk MYCN amplified (MNA) tumors
and that low miR-497 expression was associated with worse EFS and OS in our cohort. Over-expression of miR-497
reduced cell viability and increased apoptosis in MNA cells. We identified WEE1 as a novel target for miR-497 in
neuroblastoma. Furthermore, our analysis showed that high WEE1 levels are significantly associated with poor EFS
and OS in neuroblastoma and that siRNA knockdown of WEE1 in MNA cell lines results in significant levels of
apoptosis, supporting an oncogenic role of WEE1 in neuroblastoma. Cisplatin (CDDP) treatment of both miR-497
over-expressing cells and WEE1 inhibited cells, resulted in a significant increase in apoptosis in MNA cells, describing
a synergistic effect and therefore a potential therapeutic for high-risk neuroblastoma.
Conclusion: Our study’s results are consistent with miR-497 being a candidate tumor suppressor in neuroblastoma,
through the direct targeting of WEE1. These findings re-enforce the proposal of WEE1 as a therapeutic target in
neuroblastoma.
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Introduction
Neuroblastoma, a paediatric cancer that originates from
precursor cells of the sympathetic nervous system, is re-
sponsible for 15% of all childhood cancer deaths [1]. Tu-
mors display a high level of heterogeneity, with clinical
outcome ranging from spontaneous regression without
treatment, to rapid disease progression and mortality [2,3].
Patients are risk stratified according to the identification
of several prognostic factors at diagnosis including; le-
vel of disease dissemination (defined by the International
Neuroblastoma Staging System (INSS)), age, histology,
and presence of high-risk genetic features such as amplifi-
cation of the MYCN proto-oncogene and chromosomal
gains (17q) and deletions (11q or 1p) [1,4]. Despite ad-
vances in treatment and disease management, the over-
all 5-year survival rates remain poor in high-risk disease
(25-40%). Further elucidation of the underlying mecha-
nisms of neuroblastoma disease, and recent advances in
understanding the molecular basis of high-risk neuroblast-
oma may contribute to a greater understanding of re-
sponse to therapy and outcome, potentially leading to the
identification of suitable therapeutic targets that may re-
spond to novel agents [5,6].
MicroRNAs (miRNAs) are a class of short non-coding
RNAs that have emerged as significant epigenetic regula-
tors of cellular functions, predominantly through silencing
of their target genes via direct complementary mRNA 3′
UTR base pairing. Dysregulation of miRNAs has been
reported in numerous cancers where individual miRNA
behave in an oncogenic or tumor suppressor manner
[7,8]. To date, several profiling studies have identified
miRNAs that are associated with clinical outcome in
neuroblastoma [9-13] and specific miRNAs have been
identified that regulate key processes such as apoptosis,
differentiation, cell proliferation and cell invasiveness in
neuroblastoma [14-17].
MiR-497 was previously identified by our laboratory as
a member of a miRNA expression signature that is pre-
dictive of neuroblastoma patient survival [9], and has
also been reported to play a tumor suppressor role in a
variety of other cancers [18-20]. Down-regulation of
miR-497 has been reported in both multidrug resis-
tant lung and gastric cancer cell lines, compared to
non-resistant cell lines [21]. Recently, BCL2 (a known
anti-apoptotic protein determined to be involved with
neuroblastoma drug resistance) has been demonstrated
as a direct target of miR-497 in neuroblastoma cells [22],
further highlighting an important tumor suppressor role
of this miRNA in this cancer.
WEE1, a tyrosine kinase regulator of the cell cycle, is
over-expressed in several cancer types, including hepato-
cellular carcinoma and breast cancer and is also associated
with poor disease free survival in malignant melanoma
[23-25]. WEE1 expression has been demonstrated to
prevent ovarian cancer cells from undergoing apoptosis in
response to DNA damage [26]. WEE1 inhibition, in breast
cancer, results in a significant decrease in cell proliferation
and increased apoptotic levels. This effect is mirrored by
inhibition of WEE1 in cells exposed to DNA damaging
agents in glioblastoma [27,28].
Here we report that low miR-497 expression levels
are associated with event free survival (EFS) and overall
survival (OS) in our neuroblastoma cohort and describe
a significant difference in miR-497 expression between
MYCN-amplified (MNA) versus non-MYCN-amplified
(non-MNA) tumors. We demonstrate that miR-497
over-expression results in significantly decreased cell
viability through increased apoptotic rates in MNA
neuroblastoma cells, in part, through the direct tar-
geting of the 3′UTR of WEE1. Furthermore, we observe
that higher than median WEE1 levels are significantly
associated with poor EFS and OS in neuroblastoma and
that siRNA knockdown of WEE1 in MNA neuroblast-
oma cell lines results in significant and profound levels
of apoptosis, supporting an oncogenic role of WEE1 in
neuroblastoma. Treatment of either miR-497 over-
expressing cells or WEE1 inhibited cells with CDDP
resulted in a significant increase in apoptotic rates in
MNA neuroblastoma cells. The synergistic enhance-
ment of CDDP induced apoptosis through miRNA or
siRNA mediated WEE1 inhibition indicates a potential
therapeutic strategy for high risk neuroblastoma.
Results
MiR-497 expression is significantly associated with event
free and overall survival in neuroblastoma
Analysis of miR-497 expression levels in 143 primary diag-
nostic neuroblastoma samples (Additional file 1: Table S1)
revealed significantly lower expression of miR-497 (based
on median expression) in patients with known higher risk
prognostic factors including MYCN amplification (MNA)
and INSS Stage 4 disease (Figure 1A). Although miR-497
was found not to be independent of other known risk fac-
tors (Additional file 2: Table S2), higher expression (> first
quartile) of miR-497 was significantly associated with both
improved event free survival (EFS 5 year 65% vs 16%) and
overall survival (OS 5 year 84% vs 21%), indicating a poten-
tial tumor suppressor role in neuroblastoma (Figure 1B).
Ectopic expression of miR-497 decreases cell viability and
increases apoptotic rates in neuroblastoma cells in vitro
To further investigate a potential tumor suppressor role of
miR-497 in neuroblastoma, we observed the effects of
miR-497 over-expression on neuroblastoma cell viability, by
transiently transfecting mature miR-497 mimics into MNA
Kelly and CHP-212 cell lines and non-MNA SK-N-AS cell
line. MiR-497 expression was significantly up-regulated
following transfection in all cell lines (Additional file 3:
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Figure S1). Ectopic expression of miR-497 resulted in sig-
nificantly decreased cell viability in the MNA Kelly and
CHP-212 cell lines at 96 hr relative to negative controls,
while lowered cell viability observed in SK-N-AS was not
statistically significant (Figure 2A).
Consistent with these results, a significant increase in
apoptosis activity was observed in MNA Kelly and
CHP-212 cells following miR-497 transfection, as deter-
mined by Annexin V/PI staining and FACs analysis at
96 hr following miR-497 transfection (Figure 2B). No
change in the rate of apoptotic cell death was detected for
SK-N-AS (Figure 2B). Representative scatter plots for
Kelly and CHP-212 are illustrated (Figure 2D). A signifi-
cant increase in caspase 3/7 activation was observed in
MNA Kelly and CHP-212 cells when compared to nega-
tive controls. Consistent with both cell viability and
Annexin V assays, no change in caspase activation was ob-
served in non-MNA SK-N-AS cells (Figure 2C). We also
note that Kelly and CHP-212 cells became rounded and
detached following miR-497 over-expression, consistent
with apoptosis, whereas SK-N-AS cells remained attached
to the dish (Figure 2E). We conclude that miR-497 de-
creases cell viability in MNA neuroblastoma Kelly and
CHP-212 cells through an increase in apoptotic rates.
Consistent with the above results, cell cycle analysis of
MNA Kelly cells revealed a significant increase in cell
number in the G0/G1 phase of the cell cycle following
over-expression of miR-497 when compared to negative
controls. A corresponding significant decrease in the
number of cells in the G2/M of the cell cycle was ob-
served, following over-expression of miR-497 when com-
pared to negative controls. These results further support
the apoptotic phenotype following miR-497 over-
expression (Additional file 4: Figure S4A). Representative
cell cycle analysis plots of MNA Kelly cells are illustrated
(Additional file 4: Figure S4C). MiR-497 targets the 3′UTR
of WEE1 in neuroblastoma cells. Through In silico analysis
(using the algorithms TargetScan, miRDB and miRanda),
we examined all computationally predicted target genes of
miR-497. WEE1 was a computationally predicted target of
interest given our observed phenotypic effect of de-
creased cell viability and increased apoptotic rates
Figure 1 miR-497 expression is significantly associated with risk and survival in a neuroblastoma cohort (n=143). (A) Box and whiskers
plots represent the expression of miR-497 in a cohort of 143 primary neuroblastoma tumors. Samples are grouped according to known risk
factors and expression compared in each of; MYCN amplified versus Non MYCN amplified or Stage 4 versus INSS Stage 1,2,3,4S. Statistical
differences in median expression were analysed using two sided Mann–Whitney U tests. Dark shading indicates known higher risk factor.
HR= Hazard Ratio. (B) Kaplan-Meier plots for event free survival (EFS) and overall survival (OS) in 143 neuroblastoma patients. P values were
obtained using log-rank test.
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Figure 2 Ectopic expression of miR-497 decreases cell viability and increases apoptotic rates in vitro. (A) Neuroblastoma MYCN-amplified
cell lines Kelly (n=3), CHP-212 (n=3) and non-MYCN-amplified SK-N-AS (n=3) were transfected with miR-497 mimics/scrambled negative control
(Neg Control) oligonucleotides. Viability of cells was measured by MTS assay at 24 hr, 48 hr, 72 hr and 96 hr post transfection. (B) Mean
percentage of annexin V+ Kelly, CHP-212 and SK-N-AS cells, from at least three independent experiments at 96 hr post transfection with miR-497
mimic/Scrambled NC. (C) Caspase 3/7 activation was measured at 72 h post transfection (n=3, each × 5 technical replicates) in Kelly, CHP-212
and SK-N-AS cell lines, (D) Representative Annexin V Scatter plots for neuroblastoma MYCN-amplified Kelly and CHP-212 cells following
transfection with miR-497 mimics/scrambled negative control (Neg Control) oligonucleotides. (E) Images of miR-497 over-expressing cells vs
scrambled negative controls (Neg Control) in Kelly, CHP-212 and SK-N-AS.
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Figure 3 (See legend on next page.)
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following miR-497 over-expression, and WEE1’s docu-
mented role as a negative regulator of CDC2 mediated
apoptosis [29]. WEE1 has two conserved 7-mer seed
matches with miR-497 in its 3′UTR (Figure 3A).
Ectopic expression of miR-497 mimics in Kelly, CHP-212
and SK-N-AS cells resulted in knockdown of WEE1 protein
but not mRNA, indicating that the miRNA had a potential
inhibitory effect on translation (Figure 3B,C). Densitometry
analysis shows significant decrease in WEE1 protein levels
following miR-497 over-expression when compared to
negative controls (Figure 3D). To determine if miR-497 dir-
ectly targets the 3′ UTR of WEE1, luciferase reporter plas-
mids were constructed containing a 450 bp segment of
the WEE1 3′ UTR with either the wild type or a mutated
miR-497 seed site. As miR-497 has two potential binding
sites in the 3′UTR of WEE1, mutant reporter constructs
were made that had either single mutated sites or both sites
mutated (Additional file 5: Figure S2). Co-transfection of
the reporter construct containing the wild-type binding se-
quence with mature miR-497 mimics resulted in a statisti-
cally significant reduction in luciferase activity in Kelly cells
(Figure 3E). Luciferase activity was also significantly re-
duced in both reporter constructs with only one of the two
potential miR-497 binding sites mutated. This effect was
abrogated by a double mutated target sequence, thereby
confirming that WEE1 is directly targeted by miR-497
(Figure 3E).
siRNA mediated WEE1 knockdown represents a potent
mechanism of apoptosis induction in neuroblastoma cells
in vitro
Analysis of WEE1 expression levels in 88 primary diag-
nostic neuroblastoma samples revealed a significant as-
sociation of high WEE1 expression with poor EFS and
OS. Further analysis of this data set revealed no signifi-
cant difference in the median expression of WEE1 in tu-
mors with/without MNA but a significant difference for
WEE1 median expression levels between tumors from
INSS Stage 4 versus Stage 1,2,3 and 4 s disease
(Figure 4A).
To test the hypothesis that miR-497 targeting of
WEE1 might contribute, in part, to the biological effects
of miR-497, we performed siRNA mediated inhibition of
WEE1. WEE1 was significantly reduced at both mRNA
and protein levels following siWEE1 transfection of
Kelly, CHP212 and SK-N-AS cells (Additional file 6:
Figure S3A and B). siWEE1 resulted in significantly de-
creased cell viability in Kelly, CHP-212 and SK-N-AS
cell lines at both 72 hr and 96 hr time points relative to
negative controls (Figure 4B). Given that siRNA me-
diated inhibition of WEE1, a now validated target of
miR-497, had a similar phenotypic effect on our neuro-
blastoma cell lines, Annexin V/PI assays were performed
using siWEE1.
Following WEE1 inhibition, significantly increased levels
of apoptosis (Annexin V+) were observed relative to nega-
tive controls at 96 hr for both Kelly and CHP-212. How-
ever, in SK-N-AS cells, there was not a significant increase
in apoptotic cell numbers (Figure 4C). siRNA mediated
inhibition of WEE1 in Kelly and CHP-212 cells resulted in
the cells becoming rounded and detached, similar to the
morphological changes observed following miR-497 over-
expression. SK-N-AS cells, however, retained their morph-
ology and remained attached to the dish, consistent with
results produced by miR-497 ectopic over-expression.
Taken together, our results indicate that WEE1 knock-
down mediated by either miR-497 or siRNA in SK-N-AS
results in a reduction in cell proliferation without causing
increased apoptosis (Figure 4D). Consistent with the above
results, cell cycle analysis of MNA Kelly cells revealed a
significant increase in cell number in the G0/G1 phase of
the cell cycle following WEE1 inhibition when compared
to negative controls. A corresponding significant de-
crease in the number of cells in the G2/M of the cell
cycle following WEE1 inhibition was observed, when
compared to negative controls. These results further
support the apoptotic phenotype following WEE1 inhib-
ition (Additional file 4: Figure S4B). Representative cell
cycle analysis plots of MNA Kelly cells are illustrated
(Additional file 4: Figure S4D).
CDDP treatment combined with ectopic expression of
miR-497 or siRNA mediated knockdown of WEE1 results
in increased apoptotic rates in neuroblastoma cells
in vitro
In order to elucidate how miR-497 may contribute to im-
proved patient survival, we assessed the effect of miR-
497 over-expression and siRNA mediated knockdown of
WEE1 on apoptotic rates in Kelly, CHP-212 and SK-N-AS
cell lines in response to CDDP. Following transfection
(See figure on previous page.)
Figure 3 MiR-497 targets the 3′UTR of WEE1 in neuroblastoma cells. (A) Two conserved 7-mer seed matches with hsa-miR-497 in WEE1 3′
UTR. (B) WEE1 mRNA expression levels 24 hours after transfection with miR-497 compared to negative controls in neuroblastoma MYCN-amplified
cell lines Kelly (n=3), CHP-212 (n=3) and non-MYCN-amplified SK-N-AS (n=3). (C) WEE1 protein levels, following transfection with miR-497 mimics
or scrambled negative control, determined by western blot of protein extraction at 96 hrs. (D)Densitometry analysis of WEE1 protein levels
following miR-497 over-expression in Kelly, CHP-212 and SK-N-AS cells. (E) Kelly cells were co-transfected with miR-497 mimics or Scrambled
negative control and either wild-type (WT) or mutated (mut) WEE1 3′UTR reporter constructs. Luciferase activity was determined 48 hrs
post transfection.
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with miR-497 mimics and treatment with 5ug/ml CDDP, a
significant increase in apoptotic cells (Annexin V+) was
detected in Kelly and CHP-212 (Figure 5A) relative to nega-
tive controls. These cell lines also displayed increased
apoptosis in response to siRNA mediatedWEE1 inhibition
and treatment with 5ug/ml CDDP (Figure 5B). SK-N-AS
exhibited a significant increase in apoptosis in response
to siRNA mediated WEE1 inhibition and treatment with
5ug/ml CDDP, but not in response to miR-497 and
CDDP (Figure 5A,B), compared to negative controls.
Representative scatter plots for Kelly are illustrated
(Figure 5C,D).
Figure 4 siRNA mediated inhibition of WEE1 results in decreased cell viability and increased apoptosis in vitro. (A) Kaplan-Meier plots for
EFS and OS in 88 neuroblastoma patients (Amsterdam) based on median WEE1 mRNA expression. P values were obtained using log-rank test. Box
and whiskers plots represent the expression of WEE1 in a cohort of 88 primary neuroblastoma tumors. Samples are grouped according to known
risk factors and expression compared in each of; MYCN amplified versus Non MYCN amplified and INSS Stage 4 versus INSS Stage 1,2,3,4S.
Statistical differences in median expression were analysed using two sided Mann–Whitney U tests. Dark shading indicates known higher risk
factor. HR= Hazard Ratio. (B) Neuroblastoma MYCN-amplified cell lines Kelly (n=3), CHP-212 (n=3) and non-MYCN-amplified SK-N-AS (n=3) were
transfected with siWEE1 /siNegative control (siNeg Control). Viability of cells was measured by MTS assay at 24 hr, 48 hr, 72 hr and 96 hr post
transfection. (C) Mean percentage of annexin V+ Kelly, CHP-212 and SK-N-AS cells, from at least three independent experiments at 96 hr post
transfection with siWEE1 /siNegative control (siNeg Control). (D) Images of siWEE1 inhibited cells versus siNegative controls (siNeg Control) in
Kelly, CHP-212 and SK-N-AS.
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Discussion
The dysregulation of miRNAs is a key mechanism in-
volved in the pathogenesis of neuroblastoma, with sev-
eral tumor suppressor miRNAs having been identified
[11,14-17,30,31]. Here we determined that expression of
miR-497, another potential tumor suppressor in neuro-
blastoma, was significantly lower in high-risk MYCN
amplified tumors and that lower miR-497 expression
was associated with worse EFS and OS in our patient co-
hort. Similarly, miR-497 expression has been associated
with improved patient survival in other cancers, includ-
ing breast and colorectal cancer (CRC), suggesting a
wider tumor suppressor role for this miRNA [18,19]. Ec-
topic expression of miR-497 decreased breast cancer cell
proliferation and increased apoptosis in colorectal can-
cer cell lines [18,19]. Similarly, we observed a significant
increase in apoptosis in our MNA neuroblastoma cell
lines following over-expression of miR-497 in vitro.
To date, the characterisation of miR-497 function has
not been extensive, although several targets have been
identified with a key role in cell cycle and survival path-
ways, including BCL2, CCND2 and IGF1-R [18,21,22].
We have identified a novel target of miR-497, WEE1
tyrosine kinase, an emerging novel therapy target and
Figure 5 Cells transfected with miR-497 mimics or siWEE1 followed by CDDP treatment. (A) Neuroblastoma MYCN-amplified cell lines Kelly,
CHP-212 and non-MNA SK-N-AS were transfected with miR-497 mimics/scrambled negative control (Neg Control) oligonucleotides. At 48 hr post
transfection, cells were treated for 24 hr with 5 μg/ml concentration of CDDP. Media was replaced for a further 24 hrs. Mean percentage of
annexin V+ Kelly, CHP-212 and SK-N-AS cells, from at least three independent experiments at 96 hr post transfection (B) Neuroblastoma
MYCN-amplified cell lines Kelly, CHP-212 and non-MNA SK-N-AS were transfected with siWEE1 /siNegative control (siNeg Control). At 48 hrs post
transfection, cells were treated for 24 hr with 5 μg/ml concentration of CDDP. Media was replaced for a further 24 hr.Mean percentage of
annexin V+ Kelly, CHP-212 and SK-N-AS cells, from at least three independent experiments at 96 hr post transfection (C) Representative Annexin V
Scatter plots for neuroblastoma MYCN-amplified Kelly cells following transfection with miR-497 mimics/scrambled negative control (Neg Control)
oligonucleotides and 5 μg/ml CDDP treatment. (D) Representative Annexin V Scatter plots for neuroblastoma MYCN-amplified Kelly cells
following transfection with siWEE1 /siNegative control (siNeg Control) and 5 μg/ml CDDP treatment.
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potent pro-survival protein in neuroblastoma. WEE1, an
important regulator at the G2 checkpoint, normally
negatively regulates entry into mitosis through phos-
phorylation of Tyr15 on CDC2 [29]. Several studies have
identified that WEE1 is essential for normal cell function
and embryonic development [32,33]. WEE1 has been as-
sociated with survival in several other cancer types in-
cluding glioblastoma, malignant melanoma and breast
cancer [25,27,28]. This is consistent with our findings as
the analysis of WEE1 expression levels in an independ-
ent cohort of 88 primary diagnostic neuroblastoma sam-
ples revealed a significant association of high WEE1
expression with poor EFS and OS.
An interesting study on CD34+ umbilical cord blood
cells by Lei et al., focused on the anti-apoptotic role of
WEE1. They showed that when these cells were treated
with chemotherapeutic agents, including CDDP, the
over-expression of WEE1 supported cell viability and
resulted in decreased apoptosis [34]. Subsequent studies
have identified that knockdown of WEE1, including
siRNA mediated knockdown or the use of the novel
WEE1 inhibitor MK-1775, successfully enhances the re-
sponse to chemotherapy through abrogation of G2 arrest
and increased apoptosis [28,35]. The therapeutic applica-
tion of combined MK-1775 and chemotherapy has been
confirmed in preclinical studies and results of clinical
studies evaluating MK-1775 are awaited [36].
Russell et al., described how down-regulation of WEE1
protein in neuroblastoma MNA cell lines resulted in sig-
nificantly increased apoptosis, making this an attractive
potential target for novel therapy approaches in high-
risk neuroblastoma [37]. We determined that miR-497
directly targets and inhibits WEE1 protein expression in
neuroblastoma cell lines, resulting in increased apop-
tosis. Russell et al., reported that sensitivity to a WEE1
inhibitor (MK-1775) correlated with MYCN dosage [37],
consistent with our findings that miR-497 inhibition of
WEE1 produced a more significant increase in apoptosis
in MNA neuroblastoma cell lines compared to the non-
MNA SK-N-AS cell line. Even siRNA mediated WEE1 in-
hibition did not result in an apoptotic increase for SK-N
-AS, although a significant reduction in cell growth oc-
curred. However, following siRNA WEE1 knockdown and
treatment with CDDP, a significant increase in apoptotic
levels was recorded in both MNA and non-MNA cell
lines. The different phenotypic response observed between
MNA and non-MNA cell lines following siRNA mediated
inhibition of WEE1 and ectopic expression of miR-497,
when combined with CDDP, may be reasonably explained.
siWEE1 is specifically designed and has been optimised
for maximal knock-down of WEE1, whereas, miR-497, al-
though directly targeting WEE1, may act in concert with
other regulatory factors. siRNA mediated knockdown of
WEE1 is more potent than the knockdown of WEE1
observed following miR-497 over-expression (Figure 3C,
3D and Additional file 6: Figure S3B, S3Cf ). Given the
significantly increased level of WEE1 protein knock-
down following transfection with siWEE1 when com-
pared to the level of WEE1 protein knockdown
following miR-497 over-expression, this may explain the
significant increase in apoptotic levels in SK-N-AS when
combined with CDDP treatment.
One of the main obstacles in cancer treatment is the re-
sistance of cancer cells to anti-cancer therapy. miRNAs
have been linked to the development of drug resistance in
several cancers [38]. Recently, we demonstrated that
miR-204 increases sensitivity of neuroblastoma cells to
CDDP, in part, through the down-regulation of BCL2 [31].
MiR-497 has also been implicated in the development of
multi-drug resistance in human gastric and lung cancer
cell lines, at least in part, through targeting of anti-
apoptotic BCL2 [21]. BCL2 has also been demonstrated as
a direct target of miR-497 in neuroblastoma [22], although
BCL2 knockdown alone only increases apoptosis in a cell
line specific manner [31].
Conclusions
Our study’s findings of the significant anti-proliferative
effects of miR-497 further corroborate a tumor suppres-
sive role for miR-497 in neuroblastoma, through the dir-
ect targeting of WEE1. Considering the significant
increase in apoptosis due to WEE1 knock-down alone in
MNA cell lines, or WEE1 knockdown in combination
with CDDP in both MNA and non-MNA cell lines, fur-
ther investigation of WEE1 as a potentially important
therapeutic target in neuroblastoma is warranted.
Materials and methods
Primary neuroblastoma tumors
Primary neuroblastoma tumor samples (n=143) were
obtained from the Children’s Oncology Group (COG),
Philadelphia, USA (n=112) or from Our Lady’s Children’s
Hospital, Dublin, Ireland (n=31) (Additional file 1:
Table S1). Research was approved by the Research Ethics
Committees of the Royal College of Surgeons and Our
Lady’s Children’s Hospital, Dublin. Detailed miRNA ex-
pression profiling of this cohort of patients is described
previously [9]. An independent data set of 88 primary
neuroblastoma tumors was also used as part of the ana-
lysis for this study. This data is readily available using
the web based R2 microarray analysis and visualization
platform from the Academic Medical Center (AMC),
Amsterdam (http://hgserver1.amc.nl/cgi-bin/r2/main.cgi).
Cell culture and transfections
Neuroblastoma cell lines including Kelly and CHP-212
(MYCN amplified) and SK-N-AS (non-MYCN amplified)
were purchased from the European Collection of Animal
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Cells. All lines were validated by short tandem repeat se-
quence genotyping and for presence of previously pub-
lished genomic imbalances using array comparative
genomic hybridisation (aCGH). Cell culture media was
supplemented with 10% FBS and 1% Pen/Strep.
MiR-497 mimics and scrambled control oligonucleo-
tides (Ambion, Life Technologies, Carlsbad, CA, USA)
were transiently transfected in neuroblastoma cells at a
final concentration of 30 nM by reverse transfection
using siPORT™ NeoFX™ (Ambion). For siRNAs (siRNA
negative control and siWEE1 final concentration 30nM
(Ambion)), and in the co-transfection of luciferase re-
porter plasmids and miR mimics, cells were transiently
transfected using Lipofectamine 2000 (Invitrogen).
Cell viability and apoptosis assays
Viability of cells was measured by MTS-formazan reduc-
tion using CellTiter 96 Aqueous One Solution Cell Prolif-
eration Assay (Promega, Madison, WI, USA) at 24 hr,
48 hr, 72 hr, and 96 hr post transfection. Absorbance was
measured at 490 nm using a Synergy Multi-Mode Plate
Reader (Boitek, Winooski, VT, USA). Apoptosis levels
were demonstrated by Annexin-V staining and propidium
iodide (PI) exclusion using the FITC Annexin-VApoptosis
Detection Kit I (BD Pharmingen, San Diego, CA, USA).
Cells were acquired using a BD LSR II flow cytometer
(Becton Dickinson, San Jose, CA, USA) and analysed
using BD FACSDiva 4.0 Software. Caspase 3/7 activity was
evaluated using the Caspase-GloW 3/7 Assay (Promega)
and luminescence recorded using a Synergy Multi-Mode
Plate Reader (Boitek).
Quantitative real-time RT-PCR
Total RNA was extracted from cell lines using
miRNeasy Mini Kits (Qiagen, Valencia, CA, USA). Re-
verse transcription was performed using total RNA with
primers specific for miR-497 or RNU48 control and
TaqMan microRNA reverse transcription kit (Applied
Biosystems Life Technologes, Carlsbad, California, USA).
For gene expression analysis, reverse transcription was
performed using High-Capacity reverse transcription kits
(Applied Biosystems). Specific TaqMan assays (Applied
Biosystems) for WEE1 and miR-497 were employed for
expression analysis on the 7900 HT Fast Realtime System
(Applied Biosystems). MiRNA and gene expression was
normalised using the endogenous controls RNU48 and
18S respectively and relative quantities determined by the
delta CT method [39].
Western blot analysis
Total protein was analysed by western blotting using pri-
mary antibodies anti-WEE1 (B11) (Santa Cruz Biotech-
nology, Santa Cruz, CA, U.S.A), followed by anti-mouse
secondary antibody (Cell Signaling Technology, Beverly,
MA USA) and anti-mouse alpha-tubulin loading control
(Abcam,Cambridge, MA USA).
Luciferase reporter assay
Direct targeting of the WEE1 3′UTRs was determined
by cloning of the 3′UTR seed region and mutated seed
regions into separate psiCHECK™-2 vectors (Eurofins
MWG Operon, Anzingerstr Ebersberg Germany). Renilla
and firefly luciferase activities were measured using the
Dual-LuciferaseW Reporter kit (Promega) and lumines-
cence recorded on a Synergy Multi-Mode Plate Reader
(Boitek).
Cell cycle analysis
Cell cycle progression and proliferation was monitored
using the Cell Cycle Assay Kit - Green Fluorometric at
48 hr post transfection (Abcam Cambridge, MA USA).
Cells were acquired using a BD LSR II flow cytometer
(Becton Dickinson, San Jose, CA, USA) and analysed using
Weasel 3.1 Software
Statistical analysis
All statistical analysis was performed using GraphPad prism
5 software (GraphPad Software, San Diego, CA, USA) or
MedCalc Version 12.2.1.0 (MedCalc Software, Mariakerke,
Belgium). A P-value of <0.05 was regarded as statistically
significant (* p < 0.05; ** P < 0.01; *** P < 0.001).
Additional files
Additional file 1: Table S1. Neuroblastoma Cohort Clinical Data.
Additional file 2: Table S2. Multivariate (Cox proportional hazard
regression) analysis of event free and overall survival in 143
neuroblastoma patients.
Additional file 3: Figure S1. miR-497 mRNA expression following
transfection with miR-497 mimics. Neuroblastoma MYCN-amplified cell
lines Kelly (n=4), CHP-212 (n=4) and non-MYCN-amplified SK-N-AS (n=3)
were transfected with miR-497 mimics/scrambled negative control (Neg
Control) oligonucleotides. Upregulation of miR-497 mRNA expression
levels compared to negative controls. Total RNA isolated 24 hrs post
transfection.
Additional file 4: Figure S4. Cell cycle analysis of MNA Kelly cells
following miR-497 over-expression and siRNA mediated inhibition of
WEE1. (A) Cell cycle analysis of MNA Kelly cells transfected with miR-497
mimics/scrambled negative controls (Neg Control) oligonucleotides.
Mean percentage of cells in G0/G1 and G2/M phases of the cell cycle
from three independent experiments at 48 hr post transfection. (B) Cell
cycle analysis of MNA Kelly cells transfected with siWEE1/ siNegative
control (siNEG Control). Mean percentage of cells in G0/G1 and G2/M
phases of the cell cycle from three independent experiments at 48 hr
post transfection. (C) Representative cell cycle plots for MNA Kelly
following transfection with miR-497 mimics/scrambled negative control
(Neg Control) oligonucleotides. (D) Representative cell cycle plots for
MNA Kelly following transfection with siWEE1 /siNegative control
(siNeg Control).
Additional file 5: Figure S2. 3′UTR sequences from WEE1 cloned into
the luciferase reporter constructs. The miR-497 binding sites, or mutated
sequence is underlined.
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Additional file 6: Figure S3. WEE1 mRNA and protein expression
following siRNA mediated inhibition of WEE1. Neuroblastoma MYCN-
amplified cell lines Kelly (n=3), CHP-212 (n=3) and non-MYCN-amplified
SK-N-AS (n=3) were transfected with siWEE1/siNegative control (Neg
Control) oligonucleotides (A) Downregulation of WEE1 mRNA expression
levels following siWEE1 compared to negative controls. Total RNA was
isolated 24 hr post transfection. (B) Downregulation of WEE1 protein
levels following siWEE1 compared to negative controls. Protein was
isolated at 48 hrs post transfection.
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